Recurrent Prostate Cancer - Healing Genes

Recurrent Prostate Cancer

Share This Post

Share on facebook
Share on linkedin
Share on twitter
Share on email

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer (PrTK03)

A Randomized Controlled Trial of ProstAtak® as Adjuvant to Up-front Radiation Therapy For Localized Prostate Cancer

Phase 3


Researchers at 57 US study centers are recruiting over 700 participants to trial a prostate cancer immunotherapy that both kills cancer cells by imparting a suicide gene and stimulates the body’s immune system to find and kill cancer cells. ProstAtak, the investigatory drug, will be administered to the tumor in combination with radiation and valocyclovir medicine. Follow up will continue every 6 months for 5 years. One third of participants will receive a placebo, but neither the researchers nor the patients will know which they are receiving.

If effective, the treatment is expected to improve outcomes for the patients.


  • Be 18 years of age or older and male
  • Have a diagnosis of prostate cancer meeting clinical criteria
  • Not have a known sensitivity or allergic reactions to acyclovir or valacyclovir


  1. Prescreening tests to confirm eligibility of the patient to participate.
  2. Three courses of ProstAtak® each consisting of AdV-tk injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate 15 – 56 days before radiation, ~3 days before radiation, and then 15-22 days post radiation.
  3. Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification.
  4. The prodrug valacyclovir will be administered by mouth at a fixed dose for 14 days after each ProstAtak® injection.
  5. Follow up will continue each 6 months for up to 5 years.


57 study sites are participating across the US. See the full list, along with contact information, here.



Advantagene, Inc.


Or go online:

Subscribe To Our Newsletter

Get updates and learn from the best

More To Explore

Vanquishing the Virus: 160+ COVID-19 Drug and Vaccine Candidates in Development

While President Trump continues to promote antimalarial drugs such as hydroxychloroquine sulfate and azithromycin to treat COVID-19—“What do you have to lose?” he exclaimed during the April 4 Coronavirus Task Force Briefing—the global community of drug discovery researchers and biopharmas is developing a much broader